Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


14.01.2019

2 Acta Cytol
1 AJR Am J Roentgenol
2 Am J Epidemiol
1 Am J Surg Pathol
6 Ann Oncol
4 Anticancer Res
6 BMC Cancer
2 Breast Cancer
1 Breast Cancer Res
25 Breast Cancer Res Treat
3 Cancer
1 Cancer Cell
1 Cancer Chemother Pharmacol
1 Cancer Res
2 Clin Breast Cancer
1 Eur J Surg Oncol
1 Eur Radiol
1 Gene
1 Int J Cancer
3 Int J Oncol
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
3 J Natl Cancer Inst
1 J Surg Oncol
1 N Engl J Med
1 Oncogene
2 Oncol Rep
7 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Cytol

  1. RODRIGUEZ EF, Chowsilpa S, Maleki Z
    The Differential Diagnosis in Nonlymphoproliferative Malignant Pleural Effusion Cytopathology and Its Correlation with Patients' Demographics.
    Acta Cytol. 2018;62.
    PubMed     Text format     Abstract available

  2. CAETANO OLIVEIRA R, Schmitt FC
    Stromal Cellular Fragments in Breast Fine Needle Aspirates: Think Outside of the Box.
    Acta Cytol. 2018;62.
    PubMed     Text format     Abstract available


    AJR Am J Roentgenol

  3. KIM S, Plemmons J, Hoang K, Chaudhuri D, et al
    Breast-Specific Gamma Imaging Versus MRI: Comparing the Diagnostic Performance in Assessing Treatment Response After Neoadjuvant Chemotherapy in Patients With Breast Cancer.
    AJR Am J Roentgenol. 2019 Jan 8:1-10. doi: 10.2214/AJR.17.18930.
    PubMed     Text format     Abstract available


    Am J Epidemiol

  4. O'BRIEN KM, White AJ, Jackson BP, Karagas MR, et al
    Toenail-Based Metal Concentrations and Young-Onset Breast Cancer.
    Am J Epidemiol. 2019 Jan 4. pii: 5273261. doi: 10.1093.
    PubMed     Text format     Abstract available

  5. O'BRIEN KM, Sandler DP, House M, Taylor JA, et al
    The influence of a breast cancer diagnosis on serum 25-hydroxyvitamin D.
    Am J Epidemiol. 2019 Jan 4. pii: 5259112. doi: 10.1093.
    PubMed     Text format     Abstract available


    Am J Surg Pathol

  6. LAURENT E, Begueret H, Bonhomme B, Veillon R, et al
    SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
    Am J Surg Pathol. 2019 Jan 8. doi: 10.1097/PAS.0000000000001216.
    PubMed     Text format     Abstract available


    Ann Oncol

  7. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
    Ann Oncol. 2019 Jan 9. pii: 5281258. doi: 10.1093.
    PubMed     Text format    

  8. BASELGA J, Manikhas A, Cortes J, Llombart A, et al
    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281256. doi: 10.1093.
    PubMed     Text format    

  9. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281259. doi: 10.1093.
    PubMed     Text format    

  10. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281263. doi: 10.1093.
    PubMed     Text format    

  11. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2019 Jan 9. pii: 5281261. doi: 10.1093.
    PubMed     Text format    

  12. WU Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, et al
    Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281255. doi: 10.1093.
    PubMed     Text format    


    Anticancer Res

  13. FREGATTI P, Gipponi M, Depaoli F, Murelli F, et al
    No Ink on Ductal Carcinoma In Situ: A Single Centre Experience.
    Anticancer Res. 2019;39:459-466.
    PubMed     Text format     Abstract available

  14. SHERBET GV, Woo WL, Dlay S
    Application of Artificial Intelligence-based Technology in Cancer Management: A Commentary on the Deployment of Artificial Neural Networks.
    Anticancer Res. 2018;38:6607-6613.
    PubMed     Text format     Abstract available

  15. EICHLER C, Fromme J, Thangarajah F, Puppe J, et al
    Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX(R) as a Function of Oncological Work Experience in 117 Cases.
    Anticancer Res. 2019;39:297-303.
    PubMed     Text format     Abstract available

  16. BAE GE, Yoon N, Cho EY, Kim HS, et al
    Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel BRAF Mutation.
    Anticancer Res. 2019;39:369-374.
    PubMed     Text format     Abstract available


    BMC Cancer

  17. SUN J, Wang X, Wang C
    Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:31.
    PubMed     Text format     Abstract available

  18. MASELLI-SCHOUERI JH, Affonso-Kaufman FA, de Melo Sette CV, Dos Santos Figueiredo FW, et al
    Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015.
    BMC Cancer. 2019;19:23.
    PubMed     Text format     Abstract available

  19. DE KRUIF JTCM, Visser M, van den Berg MMGA, Derks MJM, et al
    A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.
    BMC Cancer. 2019;19:7.
    PubMed     Text format     Abstract available

  20. MECHERA R, Soysal SD, Piscuoglio S, Ng CKY, et al
    Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    BMC Cancer. 2019;19:41.
    PubMed     Text format     Abstract available

  21. LOFTERS AK, McBride ML, Li D, Whitehead M, et al
    Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study.
    BMC Cancer. 2019;19:42.
    PubMed     Text format     Abstract available

  22. FRAMARINO-DEI-MALATESTA M, Chiarito A, Bianciardi F, Fiorelli M, et al
    Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
    BMC Cancer. 2019;19:36.
    PubMed     Text format     Abstract available


    Breast Cancer

  23. LIU L, Hu Y, Zhang S, Li X, et al
    Association of insulin-like growth factor 1 receptor and estrogen receptor with pathological complete response to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Breast Cancer. 2019 Jan 8. pii: 10.1007/s12282-018-00939.
    PubMed     Text format     Abstract available

  24. UCHIUMI K, Tsuboi K, Sato N, Ito T, et al
    Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
    Breast Cancer. 2019 Jan 4. pii: 10.1007/s12282-018-00944.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  25. SELLI C, Turnbull AK, Pearce DA, Li A, et al
    Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
    Breast Cancer Res. 2019;21:2.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  26. HASHEMI SM, Balouchi A, Al-Mawali A, Rafiemanesh H, et al
    Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05131.
    PubMed     Text format     Abstract available

  27. BARNES-KEDAR I, Bernstein-Molho R, Ginzach N, Hartmajer S, et al
    The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Breast Cancer Res Treat. 2018;172:151-157.
    PubMed     Text format     Abstract available

  28. ALSHAKER H, Srivats S, Monteil D, Wang Q, et al
    Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
    Breast Cancer Res Treat. 2018;172:33-43.
    PubMed     Text format     Abstract available

  29. PAREKH A, Fu W, Hu C, Shen CJ, et al
    Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database.
    Breast Cancer Res Treat. 2018;172:201-208.
    PubMed     Text format     Abstract available

  30. YEAP PM, Evans A, Purdie CA, Jordan LB, et al
    A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma.
    Breast Cancer Res Treat. 2018;172:381-389.
    PubMed     Text format     Abstract available

  31. TUDINI E, Moghadasi S, Parsons MT, van der Kolk L, et al
    Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Breast Cancer Res Treat. 2018;172:497-503.
    PubMed     Text format     Abstract available

  32. AUSTIN AM, Kapadia NS, Brooks GA, Onega TL, et al
    Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05098.
    PubMed     Text format     Abstract available

  33. RUGO HS, Finn RS, Dieras V, Ettl J, et al
    Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05125.
    PubMed     Text format     Abstract available

  34. GADALLA R, Hassan H, Ibrahim SA, Abdullah MS, et al
    Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05129.
    PubMed     Text format     Abstract available

  35. NITZ U, Gluz O, Christgen M, Kates RE, et al
    Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05105.
    PubMed     Text format     Abstract available

  36. STOVGAARD ES, Dyhl-Polk A, Roslind A, Balslev E, et al
    PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05130.
    PubMed     Text format     Abstract available

  37. LUBINSKI J, Huzarski T, Gronwald J, Cybulski C, et al
    Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
    Breast Cancer Res Treat. 2019 Jan 5. pii: 10.1007/s10549-018-05076.
    PubMed     Text format     Abstract available

  38. SUNG JS, Corben AD, Brooks JD, Edelweiss M, et al
    Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Breast Cancer Res Treat. 2018;172:487-496.
    PubMed     Text format     Abstract available

  39. OCANA A, Gil-Martin M, Antolin S, Atienza M, et al
    Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05100.
    PubMed     Text format     Abstract available

  40. LUSTIG DB, Warburton R, Dingee CK, Kuusk U, et al
    Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05109.
    PubMed     Text format     Abstract available

  41. YANG Z, Ouyang T, Li J, Wang T, et al
    Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05124.
    PubMed     Text format     Abstract available

  42. YAMAMOTO T, Kanaya N, Somlo G, Chen S, et al
    Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05104.
    PubMed     Text format     Abstract available

  43. ALHUDIRI IM, Nolan CC, Ellis IO, Elzagheid A, et al
    Expression of Lamin A/C in early-stage breast cancer and its prognostic value.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05092.
    PubMed     Text format     Abstract available

  44. CHENG ES, Yu XQ
    Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05101.
    PubMed     Text format    

  45. BOWDEN AR, Tischkowitz M
    Clinical implications of germline mutations in breast cancer genes: RECQL.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05096.
    PubMed     Text format     Abstract available

  46. VANE MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, et al
    Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05074.
    PubMed     Text format     Abstract available

  47. REGMI S, Fung TS, Lim S, Luo KQ, et al
    Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells.
    Breast Cancer Res Treat. 2018;172:297-312.
    PubMed     Text format     Abstract available

  48. WU NC, Wong W, Ho KE, Chu VC, et al
    Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Breast Cancer Res Treat. 2018;172:327-338.
    PubMed     Text format     Abstract available

  49. SANCHEZ-SPITMAN AB, Dezentje VO, Swen JJ, Moes DJAR, et al
    Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
    Breast Cancer Res Treat. 2018;172:401-411.
    PubMed     Text format     Abstract available

  50. NARAYAN AK, Elkin EB, Lehman CD, Morris EA, et al
    Quantifying performance thresholds for recommending screening mammography: a revealed preference analysis of USPSTF guidelines.
    Breast Cancer Res Treat. 2018;172:463-468.
    PubMed     Text format     Abstract available


    Cancer

  51. AMMITZBOLL G, Johansen C, Lanng C, Andersen EW, et al
    Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial.
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31962.
    PubMed     Text format     Abstract available

  52. TAUB CJ, Lippman ME, Hudson BI, Blomberg BB, et al
    The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment.
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31965.
    PubMed     Text format     Abstract available

  53. VEENSTRA CM, Wallner LP, Abrahamse PH, Janz NK, et al
    Understanding the engagement of key decision support persons in patient decision making around breast cancer treatment.
    Cancer. 2019 Jan 11. doi: 10.1002/cncr.31956.
    PubMed     Text format     Abstract available


    Cancer Cell

  54. SHEN M, Jiang YZ, Wei Y, Ell B, et al
    Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
    Cancer Cell. 2018 Dec 10. pii: S1535-6108(18)30537.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  55. NGUYEN TT, Angeli E, Darrouzain F, Nguyen QT, et al
    A successful compartmental approach for the treatment of breast cancer brain metastases.
    Cancer Chemother Pharmacol. 2019 Jan 5. pii: 10.1007/s00280-018-3752.
    PubMed     Text format     Abstract available


    Cancer Res

  56. KHAWALED S, Suh SS, Abdeen SK, Monin J, et al
    WWOX inhibits metastasis of triple-negative breast cancer cells via modulation of microRNAs.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-0614.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  57. ABDEL-RAHMAN O, Xu Y, Kong S, Dort J, et al
    Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study.
    Clin Breast Cancer. 2018 Dec 12. pii: S1526-8209(18)30506.
    PubMed     Text format     Abstract available

  58. LAN B, Ma F, Han M, Chen S, et al
    The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
    Clin Breast Cancer. 2018 Dec 19. pii: S1526-8209(18)30539.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  59. HEEG E, Schreuder K, Spronk PER, Oosterwijk JC, et al
    Hospital transfer after a breast cancer diagnosis: A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment.
    Eur J Surg Oncol. 2018 Dec 29. pii: S0748-7983(18)32039.
    PubMed     Text format     Abstract available


    Eur Radiol

  60. FAN M, Zhang P, Wang Y, Peng W, et al
    Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer.
    Eur Radiol. 2019 Jan 7. pii: 10.1007/s00330-018-5891.
    PubMed     Text format     Abstract available


    Gene

  61. YOUNES N, Zayed H
    Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review.
    Gene. 2019;684:154-164.
    PubMed     Text format     Abstract available


    Int J Cancer

  62. RIZZOLO P, Zelli V, Silvestri V, Valentini V, et al
    Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
    Int J Cancer. 2019 Jan 7. doi: 10.1002/ijc.32106.
    PubMed     Text format     Abstract available


    Int J Oncol

  63. LI Z, Yu D, Li H, Lv Y, et al
    Long noncoding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Int J Oncol. 2019 Jan 8. doi: 10.3892/ijo.2019.4679.
    PubMed     Text format     Abstract available

  64. JIANG M, Qiu N, Xia H, Liang H, et al
    Long noncoding RNA FOXD2AS1/miR1505p/PFN2 axis regulates breast cancer malignancy and tumorigenesis.
    Int J Oncol. 2019 Jan 3. doi: 10.3892/ijo.2019.4671.
    PubMed     Text format     Abstract available

  65. HANDA T, Katayama A, Yokobori T, Yamane A, et al
    Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.
    Int J Oncol. 2019 Jan 4. doi: 10.3892/ijo.2019.4675.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  66. BATES JE, Bradley JA
    To Treat or Not to Treat? A Postmastectomy Question.
    Int J Radiat Oncol Biol Phys. 2018;102:284.
    PubMed     Text format    

  67. BONDIAU PY, Gal J, Chapellier C, Haudebourg J, et al
    Robotic stereotactic boost in early breast cancer, a phase II trial.
    Int J Radiat Oncol Biol Phys. 2018 Oct 26. pii: S0360-3016(18)33799.
    PubMed     Text format     Abstract available


    J Clin Oncol

  68. ARASU VA, Miglioretti DL, Sprague BL, Alsheik NH, et al
    Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    J Clin Oncol. 2019 Jan 9:JCO1800378. doi: 10.1200/JCO.18.00378.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  69. REEVES KW, Santana MD, Manson JE, Hankinson SE, et al
    Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284913. doi: 10.1093.
    PubMed     Text format     Abstract available

  70. SPRAGUE BL, Kerlikowske K, Bowles EJA, Rauscher GH, et al
    Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2019 Jan 8. pii: 5280767. doi: 10.1093.
    PubMed     Text format     Abstract available

  71. HUILLARD O, Le Strat Y, Dubertret C, Goldwasser F, et al
    RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284914. doi: 10.1093.
    PubMed     Text format    


    J Surg Oncol

  72. DASGUPTA H, Islam S, Alam N, Roy A, et al
    Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
    J Surg Oncol. 2019;119:88-100.
    PubMed     Text format     Abstract available


    N Engl J Med

  73. DEFILIPPIS EM, Nohria A, Burstein HJ, Doyle LA, et al
    A Breath-Taking Diagnosis.
    N Engl J Med. 2019;380:81-87.
    PubMed     Text format    


    Oncogene

  74. DOMENICI G, Aurrekoetxea-Rodriguez I, Simoes BM, Rabano M, et al
    A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells.
    Oncogene. 2019 Jan 8. pii: 10.1038/s41388-018-0656.
    PubMed     Text format     Abstract available


    Oncol Rep

  75. WEI CW, Yu YL, Chen YH, Hung YT, et al
    Anticancer effects of methotrexate in combination with alphatocopherol and alphatocopherol succinate on triplenegative breast cancer.
    Oncol Rep. 2019 Jan 9. doi: 10.3892/or.2019.6958.
    PubMed     Text format     Abstract available

  76. HUANG S, Yuan N, Wang G, Wu F, et al
    Cellular communication promotes mammosphere growth and collective invasion through microtubulelike structures and angiogenesis.
    Oncol Rep. 2018;40:3297-3312.
    PubMed     Text format     Abstract available


    PLoS One

  77. MOUSAVI SA, Kasaeian A, Pourkasmaee M, Ghavamzadeh A, et al
    Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran.
    PLoS One. 2019;14:e0208701.
    PubMed     Text format     Abstract available

  78. WATANABE T, Yagata H, Saito M, Okada H, et al
    A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients.
    PLoS One. 2019;14:e0208118.
    PubMed     Text format     Abstract available

  79. BONSU AB, Ncama BP
    Recognizing and appraising symptoms of breast cancer as a reason for delayed presentation in Ghanaian women: A qualitative study.
    PLoS One. 2019;14:e0208773.
    PubMed     Text format     Abstract available

  80. SHARMA A, Bandyopadhayaya S, Chowdhury K, Sharma T, et al
    Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells.
    PLoS One. 2019;14:e0209435.
    PubMed     Text format     Abstract available

  81. LAI YL, Su YC, Kao CH, Liang JA, et al
    Increased risk of varicella-zoster virus infection in patients with breast cancer after adjuvant radiotherapy: A population-based cohort study.
    PLoS One. 2019;14:e0209365.
    PubMed     Text format     Abstract available

  82. LIU M, Yang Y, Xie F, Guo J, et al
    Could axillary clearance be avoided in clinically node-negative breast cancer patients with positive nodes diagnosed by ultrasound guided biopsy in the post-ACOSOG Z0011 era?
    PLoS One. 2019;14:e0210437.
    PubMed     Text format     Abstract available

  83. TEA MM, Tan YY, Staudigl C, Eibl B, et al
    Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
    PLoS One. 2018;13:e0200559.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  84. ZHANG S, Zhang H, Ghia EM, Huang J, et al
    Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
    Proc Natl Acad Sci U S A. 2019 Jan 8. pii: 1816262116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: